Abstract: The present invention is related to a method for detecting and/or quantifying hierarchical (regulated) molecular changes of a cell in response to any external stimulus.

Abstract: The invention provides a tool for the easy interpretation of the changes occurring in a cell, being a three dimensional complex and control system, by analyzing a limited number of data obtained by quantifying the intensity of the signals present on spots distributed in a two dimensional surface. These signals intensities are related to the level of genes or gene products present in the cells and after processing and data analysis, they provide an absolute or relative quantification of these genes and gene products present in the analyzed cell or tissue or organisms. The invention also provides a list of cellular functions, which are essential in order to obtain an overview of the modifications occurring in the vital or specific cellular functions under specific biological conditions.

Abstract: The present invention is directed to the identification of markers that can be used to determine the sensitivity of cancer cells to a therapeutic agent. The present invention is also directed to the identification of therapeutic targets. Nucleic acid arrays were used to determine the level of expression of sequences (genes) found in 60 different solid tumor cancer cell lines selected from the NCI 60 cancer cell line series. Expression analysis was used to identify markers associated with sensitivity to certain chemotherapeutic agents.

Abstract: The present invention is directed to the identification of markers that can be used to determine the sensitivity of cancer cells to a therapeutic agent. The present invention is also directed to the identification of therapeutic targets. Nucleic acid arrays were used to determine the level of expression of sequences (genes) found in 60 different solid tumor cancer cell lines selected from the NCI 60 cancer cell line series. Expression analysis was used to identify markers associated with sensitivity to certain chemotherapeutic agents.

Abstract: The present invention is directed to the identification of markers that can be used to determine whether cancer cells are sensitive or resistant to a therapeutic agent. The present invention is also directed to the identification of therapeutic targets. The invention features a number of “sensitivity markers.” These are markers that are expressed in most or all cell lines that are sensitive to treatment with an agent and which are not expressed (or are expressed at a rather low level) in cells that are resistant to treatment with that agent. The invention also features a number of “resistance markers.” These are markers that are expressed in most or all cell lines that are resistant to treatment with an agent and which are not expressed (or are expressed at a rather low level) in cells that are sensitive to treatment with that agent.

Abstract: Increased expression of DR6 is associated with drug resistance of certain cells (e.g., cancer cells). The invention provides methods for identifying drug resistant cells by measuring the expression or activity of DR6, methods for identifying modulators of drug resistance, and methods for modulating drug resistance by modulating the expression or activity of DR6.

Abstract: The present invention is directed to the identification of markers that can be used to determine whether cancer cells are sensitive or resistant to a therapeutic agent. The present invention is also directed to the identification of therapeutic targets. The invention features a number of “sensitivity markers.” These are markers that are expressed in most or all cell lines that are sensitive to treatment with an agent and which are not expressed (or are expressed at a rather low level) in cells that are resistant to treatment with that agent. The invention also features a number of “resistance markers.” These are markers that are expressed in most or all cell lines that are resistant to treatment with an agent and which are not expressed (or are expressed at a rather low level) in cells that are sensitive to treatment with that agent.

Abstract: The present invention is directed to the identification of markers that can be used to determine the sensitivity of cancer cells to a therapeutic agent. The present invention is also directed to the identification of therapeutic targets. Nucleic acid arrays were used to determine the level of expression of sequences (genes) found in 60 different solid tumor cancer cell lines selected from the NCI 60 cancer cell line series. Expression analysis was used to identify markers associated with sensitivity to certain chemotherapeutic agents.

Abstract: The present invention is directed to the identification of markers that can be used to determine whether cancer cells are sensitive or resistant to a therapeutic agent. The present invention is also directed to the identification of therapeutic targets. Nucleic acid arrays were used to determine the level of expression of approximately 6500 nucleic acid sequences (genes) found in 54 different solid tumor cancer cell lines selected from the NCI 60 cancer cell line series. After the level of expression was determined for each of the 6500 genes in each of the 54 cancer cell lines, statistical analysis was used to identify genes whose expression correlated with sensitivity or resistance to any one of 171 different anti-cancer compounds. Expression analysis was also used to identify genes associated with resistance or sensitivity to TAXOL in a number of cancer cell lines, clinical samples, and a human mammary epithelial cell primary cell line. The invention features a number of “sensitivity genes.